Loading...
•
Jun 30, 2024
Jaguar Health Q2 2024 Earnings Report
Reported consolidated financial results for the second quarter of 2024 and provided company updates.
Key Takeaways
Jaguar Health reported a combined net revenue of $2.72 million for Q2 2024, representing a 16% increase over Q1 2024 and a 2.0% increase compared to Q2 2023.
Combined net revenue for Q2 2024 was approximately $2.72 million, a 16% increase from Q1 2024 and a 2.0% increase from Q2 2023.
The company is completing analysis of data from the pivotal phase 3 OnTarget trial for crofelemer in cancer therapy-related diarrhea.
Jaguar plans to begin the commercial launch of Gelclair® in October 2024.
An import permit for crofelemer has been granted for a proof-of-concept trial in Abu Dhabi for pediatric patients with microvillus inclusion disease and short bowel syndrome.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health is focused on the commercial launch of Gelclair®, progressing its rare disease development business, and analyzing data from the OnTarget trial.
Positive Outlook
- Planned October 2024 commercial launch of Gelclair® in the U.S.
- Progressing rare disease development business.
- Ongoing analysis of full data for the pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD).
- Collaborating with clinical and scientific advisers to evaluate the significance of the clinically meaningful results identified in patients with breast and lung cancer in the initial data from OnTarget.
- Planning to engage in discussions with the FDA to explore the possible pathway of approval to make crofelemer available to breast and lung cancer patients for CTD.